Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 22Neoplasms 20Leukemia, Myeloid, Acute 10Ovarian Neoplasms 8Neoplasm Metastasis 7Lymphoma 7Lung Neoplasms 7Hematologic Neoplasms 6Glioblastoma 6Colorectal Neoplasms 6Prostatic Neoplasms 5Pancreatic Neoplasms 5Multiple Myeloma 5Leukemia 5Fatigue 5Stomach Neoplasms 4Depression 4Carcinoma, Non-Small-Cell Lung 4Vulvar Neoplasms 3Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pain 3Myelodysplastic Syndromes 3Motor Activity 3Melanoma 3Fallopian Tube Neoplasms 3Carcinoma, Hepatocellular 3

Interventions

Drug Therapy 2tremelimumab 1pembrolizumab 1enfortumab vedotin 1durvalumab 1atezolizumab 1Watchful Waiting 1Radiotherapy 1Palliative Care 1Magnetic Resonance Spectroscopy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle-invasive Bladder Cancer × Palliative Care × Clear all
NCT06686381 2025-02-05

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

American University of Beirut Medical Center

Phase 2 Not yet recruiting
80 enrolled
Genitourinary

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡